20-F/A: BGM Group Ltd Files Amendment No. 2 to 20-F for Fiscal Year Ended September 30, 2024

BGM Group Ltd files an amendment to its 20-F form for the fiscal year ended September 30, 2024, detailing its financial results and corporate structure.

Summary

• BGM Group Ltd, a Cayman Islands holding company, conducts its operations in China through a variable interest entity, Gansu Qilianshan Pharmaceutical Co., Ltd.
• The company has filed an amendment to its 20-F form for the fiscal year ended September 30, 2024.
• BGM's corporate structure involves contractual arrangements with the VIE, which are subject to legal and operational risks associated with operating in China.
• Investors in BGM's ordinary shares are purchasing equity interest in a Cayman Islands holding company, not in the operating entities in China.
• The company faces potential uncertainty from the PRC government, which could affect the enforceability of the contractual arrangements with the VIE.
• For the year ended September 30, 2024, net revenue was $25.1 million, a decrease of 46% compared to the previous year.
• Net loss attributable to shareholders was $1.4 million, an improvement from the $7.8 million loss in the prior year.
• The company is permitted under the laws of Cayman Islands to provide funding to its subsidiary in Hong Kong (Qilian HK) through loans or capital contributions without restrictions on the amount of the funds.
• On December 2, 2024, a filing for the issuance of 20,000,000 shares of Class B common stock to LX Management Company Limited in accordance with the Subscription Agreement was submitted to the CSRC.
• Subsequently, a filing for the issuance of 69,995,661 shares of Class A common stock to CISG Holdings Ltd. was also submitted to the CSRC on January 8, 2025.
• Both of the afore-mentioned filings are currently under review by the CSRC.

Sentiment

Score: 5

Explanation: The document presents mixed signals. While the net loss has decreased, indicating some improvement, the significant decline in revenue and the risks associated with the VIE structure and regulatory environment in China temper the overall sentiment.

Positives

• Net loss attributable to shareholders improved significantly, decreasing from $7.8 million to $1.4 million.
• EBITDA improved by $6.6 million, indicating better operational performance compared to the previous year.
• The company is permitted under the laws of Cayman Islands to provide funding to its subsidiary in Hong Kong (Qilian HK) through loans or capital contributions without restrictions on the amount of the funds.

Negatives

• Net revenue decreased by 46%, indicating a significant decline in sales.
• The company operates in China through a VIE structure, which carries legal and operational risks.
• The company faces potential uncertainty from the PRC government, which could affect the enforceability of the contractual arrangements with the VIE.

Risks

• The VIE structure is subject to regulatory risks in China, and changes in regulations could adversely affect the company's operations.
• The company relies on contractual arrangements with the VIE, which may not be as effective as direct ownership.
• The company faces competition in the pharmaceutical and chemical industries.
• The company is subject to cybersecurity, data privacy, and data protection laws and regulations in China.
• The company's Ordinary Shares may be delisted and prohibited from being traded under the Holding Foreign Companies Accountable Act if the PCAOB is unable to inspect auditors who are located in China.

Future Outlook

The company plans to continue developing its business by expanding its marketing network and investing in pharmaceutical and chemical facilities, which depend heavily on sufficient capital.

Industry Context

The pharmaceutical industry in China is highly regulated, and the company operates under a legal regime consisting of various government bodies and regulations.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• To perform a comparison, specific details about the company's performance metrics (e.g., revenue growth, profit margins) would need to be benchmarked against those of comparable companies in the Chinese pharmaceutical and chemical industries.
• Without this information, it is difficult to assess whether the company's results are above, below, or in line with industry averages.
• Some comparable companies in the Chinese pharmaceutical industry include Sinopharm Group, Shanghai Pharmaceuticals Holding, and Guangzhou Baiyunshan Pharmaceutical Holdings.
• In the chemical industry, comparables could include companies like Sinopec and PetroChina.
• A thorough analysis would require comparing BGM Group's financial ratios and operational metrics to those of these and other similar companies.

Related Party Transactions

• During the normal course of business, the VIE and VIEs subsidiaries may make sales to affiliated companies controlled by its major shareholders or subsidiaries.
• For the year ended September 30, 2024, Chengdu Qilian Trading Co., Ltd. acquired 25% ownership interest of Caihou Capital (Shenzhen) Group Co., Ltd. with a total investment amount of RMB25,000,000 in July 2024, which have been paid in the amount of RMB10,000,000 (US$1,402,584 equivalent) in 2024.
• As of September 30, 2024, the balance of due to related parties consisted of remaining payment RMB15 million (US$2,140,594 equivalent) of 25% ownership interest in Caihou and US$710,932 of construction payment advance by Ahanzhai Development Co., Ltd., which is 100% controlled by Mr. Zhanchang Xin, the chairman of the Ahanzhais board of directors.

Stakeholder Impact

• Shareholders face risks related to the VIE structure and regulatory environment in China, which could affect the value of their investment.
• Employees may be affected by changes in the company's operations and financial performance.
• Customers may be affected by changes in the availability and pricing of the company's products.
• Suppliers may be affected by changes in the company's purchasing patterns.

Next Steps

• The company needs to complete the filings with the CSRC for the issuance of shares to LX Management Company Limited and CISG Holdings Ltd.
• The company needs to monitor and adapt to changes in PRC laws and regulations that could affect its operations.
• The company needs to continue to focus on improving its internal control over financial reporting.

Key Dates

Keywords

BGM Group Ltd, VIE, Gansu Qilianshan Pharmaceutical, Financial Results, China, Ordinary Shares, PCAOB, CSRC, Regulations, Pharmaceutical, Operations, Risk Factors